Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ventura BioMed Investors is a venture capital firm based in Europe, founded by Dr. Andreas Jenne and Dr. Kurt Rudolf Schwarz, both seasoned professionals in biotech and pharmaceuticals. The firm specializes in the life sciences sector and supports early-stage companies developing innovative therapies and technologies. They typically collaborate with other funds to enhance their investment strategy.
This firm invests between €1 million and €5 million in pre-seed, seed, and seed+ stage life science companies across Europe. Their focus is on pioneering technologies and therapies, particularly in biotech and healthcare. Ventura BioMed Investors emphasizes collaboration with other funds to maximize impact.
Notable companies in Ventura BioMed Investors' portfolio include KUPANDO, which develops TLR 4/7 agonists for oncology and infectious diseases; NEOsphere Biotechnologies, focused on small molecule degraders; IRUBIS, known for its mid-infrared spectrometer system for bioprocessing; ABALOS, which is developing a virus-based anti-cancer therapy; and NAVIGNOSTICS, a spin-off from the University of Zurich specializing in spatial single-cell proteomic analysis.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.